145 results about "Biologic DMARD" patented technology

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphaVbeta3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphaVbeta3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin alphaVbeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

The present invention relates to the fields of immunology and molecular biology and describes compositions and methods for using proteins, peptides and nucleic acids related to the SARS CoV nucleocapsid protein and the spike glycoprotein. In particular, the present invention provides immunostimulatory preparations, prophylactic pharmaceutical preparations, diagnostic assays and kits for identifying and preventing SARS infections.

This invention relates to the discovery that agents capable of inhibiting the biological action of the glucocorticoid receptor can be used in methods for treating gastroesophageal reflux disease in a subject.

The present invention embodies: methods; compounds, their pharmaceutically acceptable analogs, isomer, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof that have particular biological properties; devices; diagnostic and other assays; and the uses of such methods, compounds, devices and assays. Common throughout these embodiments is specific selective reduction of intravascular thromboplastin antecedent activity, which results in a safe antithrombotic effect. A particularly prominent application or the invention relates to diagnosis and treatment of patients which have, or are at risk of, developing thrombosis, thrombotic injury, or vaso-occlusive diseases, such as myocardial infarction, stroke, restenosis after angioplasty, thrombotic diseases, etc. Another particularly prominent feature of the present invention is its high level of hemostatic safety at optimal efficacy. Also, the present invention is compatible for use in combination with other traditional therapeutic agent such as another antithrombotic, antiplatelet, thrombolytic, or anticoagulant agents.

The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods.

The compounds of the invention are modulators of cannabinoid receptors CB1 or CB2. The compounds can be used for the prevention or treatment of, e.g., pain, cancer, skin diseases, weight-associated disorders, chemical addictions, psychiatric disorders, neurodegenerative disorders, bone diseases, and inflammatory diseases. The compounds of the invention can further be used to study these diseases and disorders, as well as cannabinoid receptor biology, by coupling the compounds to, e.g., imaging agents.

The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifying additional compounds that influence TNF receptor shedding. As the active ingredient in a pharmaceutical composition, the products of this invention increase or decrease TNF signal transduction, thereby alleviating the pathology of disease.

Antagonists of alpha 4 integrin/alpha 4 integrin ligand adhesion, which inhibit the biological effects of such adhesion are described and methods for their use are detailed. Such antagonists are useful in suppressing bone destruction associated with multiple myeloma. The homing of multiple myeloma cells to bone marrow and their alpha 4 integrin-dependent release of bone-resorbing factors, resulting in bone destruction in patients with multiple myeloma, is inhibited.

Aspects of the present invention relate to molecular biology and medicine. More specifically, some embodiments include methods for treating and/or diagnosing inflammation and/or cancer using agents that inhibit the binding of a pro-inflammatory protein or protein complex (e.g., S100A8 and/or S100A9) to a carboxylated glycan expressed on a myeloid (e.g., MDSC), monocytic, dendritic, endothelial, or tumor cell.

The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one β_c Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat or prevent various diseases, disorders, or conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.

The invention belongs to the field of the tumor molecular biological, particularly relating to an oral squamous cell carcinoma diagnostic reagent, kits and medicine. The invention solves the technical problem that the existing medicine and reagent can not early diagnose oral squamous cell carcinoma and can not prevent oral carcinogenesis effectively. The invention oral squamous cell carcinoma diagnostic reagent contains the reagent which can detect expression level of protein RACK1 (activated protein kinase C receptor) and its mRNA content. The oral squamous cell carcinoma kits can be obtained with regular technology. By using the method of screening oral squamous cell carcinoma medicine, the medicine can be screened for preventing oral squamous cell carcinoma medicine, for example: by screen, obtaining effective RACK1 gene and RNA interference molecular, moreover the RNA interference result first reveals the functions of the RNA interference molecular in oral neoplasms apoptosis regulation and oral neoplasms apoptosis treatment, with broad application prospect.

The present invention provides liquid formulations of antibodies or fragments thereof that specifically bind to a hepatitis B virus (HBV) antigen, which formulations exhibit stability, low to undetectable levels of aggregations, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with HBV infection utilizing the liquid formulations of the present invention.

The invention discloses a recombination fusion protein PACAP-PTD (Pituitary Adenylate Cyclase Activating Peptide-Protein Transduction Domain) as well as an expression method and application thereof. The amino acid sequence of the recombination fusion protein PACAP-PTD provided by the invention is shown as SEQ ID NO: 1 and the nucleotide sequence encoding the protein is shown as SEQ ID NO: 2. The recombination fusion protein PACAP-PTD provided by the invention has biological activity of PACAP and gives a function of transcellular barrier transport of the PTD to the PACAP to ensure that the function of cellular barrier traversing transport can be provided, therefore, blood brain barrier, cornea, qi-blood barrier, testis barrier, endothelium and mucosa organization and the like can be effectively traversed; the application value of the PACAP-PTD in diseases related to parts of brain, eyes, lung, genitals and the like can be greatly enhanced; the route of administration can be improved; and the application range can be extended.

Methods and compositions are provided for specific aptamers and aptamer pools that bind biomarkers of interest such as microvesicle surface antigens or functional fragments of microvesicle surface antigens. In various embodiments, aptamers of the invention are used in diagnostic, prognostic, or theranostic processes to screen a biological sample for the presence or levels of biomarkers such as microvesicles that are determined to provide a diagnostic, prognostic, or theranostic readout. The diagnosis, prognosis, or theranosis may be related to cancer or other diseases and disorders. The invention also provides methods and composition to facilitate aptamer library screening and aptamer detection methods.

The invention relates to new application of interferon-induced transmembrane proteins (IFITMs) in pharmaceutical engineering, in particular to application of IFITM 3 in preparing a medicament for treating diseases related to hepatitis B virus (HBV) infection. Eukaryotic expression vectors of IFITM 1, IFITM2 and the IFITM 3 are respectively constructed by a molecular biological method in a lab; and in vivo-in vitro tests prove that the IFITM 1, the IFITM2 and the IFITM 3 can obviously inhibit HBV replication, wherein, the IFITM 3 has the most remarkable effect. Therefore, the IFITM 3 and an encoding gene thereof are expected to become novel medicaments for treating HBV-related diseases and reducing hazard of HBV-related diseases.

The invention belongs to the technical field of biological detection, and particularly relates to an HIV (human immunodeficiency virus) antigen antibody detection card and a preparation method thereof. The detection card comprises a card cover, a card body and a test strip, wherein the card cover is sequentially provided with a dilute solution adding hole, a sample adding hole, an observation hole and an installation marking hole; a groove for holding the test strip is arranged in the card body; and the test strip is sequentially provided with a sample pad layer, a colloidal gold layer, a nitrocellulose film and a water-absorbing layer. The preparation method comprises the following steps: preparing colloidal gold; respectively marking recombinant HIV-1/HIV-2 antigens and mouse anti-p24 monoclonal antibodies with the colloidal gold, marking p24 antibodies with biotin, immobilizing the colloidal gold and biotin markers, coating the nitrocellulose film, preparing the test strip, and buckling the detection card. The detection card provided by the invention can detect HIV antigen antibodies, and is high in sensitivity and low in sample consumption.

The present invention provides methods for determining the susceptibility of a pathogenic flavivirus to anti-viral compounds. This invention also provides methods for determining anti-viral drug susceptibility in a patient infected with a flavivirus. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. The methods are useful for identifying effective drug regimens for the treatment of flaviviral infections, and identifying and assessing the biological effectiveness of potential therapeutic compounds. Compositions including resistance test vectors and host cells transformed with the resistance test vectors are provided.

Antibodies and compositions capable of neutralizing oncostatin M biological functions are useful in treating diseases and disorders associated with oncostatin M, such as osteoarthritis and idiopathic pulmonary fibrosis.

A monoclonal antibody against beta-amyloid (ABeta) peptide is provided with unique immunological and biological properties useful in the immunotherapy of Alzheimer's disease. In addition, pharmaceutical compositions and kits comprising such antibody and mimics thereof in the treatment of neurological disorders such as Alzheimer's disease are described.

A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.

The invention belongs to the field of biochemistry and molecular biology and relates to a new alpha-conotoxin peptide, as well as a pharmaceutical composition, a preparation method and a use thereof. The invention further relates a propeptide, a nucleic acid construct, an expression vector, transformed cells and a fusion protein of the conotoxin peptide. The invention further relates to a method for blocking an acetylcholine receptor and a pharmaceutical use of the conotoxin peptide. The alpha-conotoxin peptide provided by the invention can specifically block the acetylcholine receptor (nAChRs (nicotinic acetylcholine receptors)) (such as alpha 6/alpha 3 beta 2 beta 3 nAChR), further has the activity in treating addiction, neuropathic pain, Parkinson's disease, dementia, schizophrenia, depression, cancers and the like and has great application prospects in preparation of medicaments for quitting smoking and drugs and relieving pain, the medicaments for treating related mental disorders and the cancers, neuroscience tool medicaments and the like.